A Narrative Review on Spontaneous Clearance of Urogenital Chlamydia trachomatis: Host, Microbiome, and Pathogen-Related Factors.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 Feb 2024
01 Feb 2024
Historique:
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
30
1
2024
Statut:
ppublish
Résumé
Chlamydia trachomatis (CT) is the most commonly reported sexually transmitted infection in the United States. Untreated urogenital infection in women can result in adverse sequelae such as pelvic inflammatory disease and infertility. Despite national screening and treatment guidelines, rates continue to rise; because most infections are asymptomatic, the actual prevalence of CT infection is likely significantly higher than reported. Spontaneous clearance of CT in women (in the absence of antibiotic treatment) has been described in multiple epidemiologic studies. Given the serious consequences and high prevalence of CT infection, there is growing interest in understanding this phenomenon and factors that may promote CT clearance in women. Spontaneous CT clearance is likely the result of complex interactions between CT, the host immune system, and the vaginal microbiota (i.e., the communities of bacteria inhabiting the vagina), which has been implicated in CT acquisition. Herein, we briefly review current literature regarding the role of each of these factors in spontaneous CT clearance, identify knowledge gaps, and discuss future directions and possible implications for the development of novel interventions that may protect against CT infection, facilitate clearance, and prevent reproductive sequelae.
Identifiants
pubmed: 38290156
doi: 10.1097/OLQ.0000000000001905
pii: 00007435-202402000-00006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112-117Informations de copyright
Copyright © 2023 American Sexually Transmitted Diseases Association. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest and Sources of Funding: J.R. is co-founder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutics drugs for women's health. S.T. has been a consultant for Biofire Diagnostics, Roche Molecular Diagnostics, and Luca Biologics; receives royalties from UPTODATE; and has received speaker honoraria from Roche Molecular Diagnostics and Medscape/WebMD.
Références
Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2021. April 11, 2023. Available at: https://www.cdc.gov/std/statistics/2021/default.htm. Accessed August 24, 2023.
Haggerty CL, Gottlieb SL, Taylor BD, et al. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010; 201(Suppl 2):S134–S155.
Hafner L, Beagley K, Timms P. Chlamydia trachomatis infection: Host immune responses and potential vaccines. Mucosal Immunol 2008; 1:116–130.
Centers for Disease Control and Prevention. Detailed STD Facts—Chlamydia. April 11. 2023. Available at: https://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm. Accessed August 24, 2023.
Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: The case for screening. Prev Med 2003; 36:502–509.
Golden MR, Schillinger JA, Markowitz L, et al. Duration of untreated genital infections with Chlamydia trachomatis: A review of the literature. Sex Transm Dis 2000; 27:329–337.
Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with chlamydia and gonorrhea among females: A systematic review of the literature. Sex Transm Dis 2009; 36:478–489.
Gaydos CA, Wright C, Wood BJ, et al. Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in school-based health centers. Sex Transm Dis 2008; 35:233–237.
Geisler WM, Lensing SY, Press CG, et al. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013; 207:1850–1856.
Hillis SD, Owens LM, Marchbanks PA, et al. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997; 176(1 Pt 1):103–107.
Tsevat DG, Wiesenfeld HC, Parks C, et al. Sexually transmitted diseases and infertility. Am J Obstet Gynecol 2017; 216:1–9.
Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev 2016; 5:210.
Parks KS, Dixon PB, Richey CM, et al. Spontaneous clearance of Chlamydia trachomatis infection in untreated patients. Sex Transm Dis 1997; 24:229–235.
Sheffield JS, Andrews WW, Klebanoff MA, et al. Spontaneous resolution of asymptomatic Chlamydia trachomatis in pregnancy. Obstet Gynecol 2005; 105:557–562.
Geisler WM, Black CM, Bandea CI, et al. Chlamydia trachomatis OmpA genotyping as a tool for studying the natural history of genital chlamydial infection. Sex Transm Infect 2008; 84:541–544 discussion 544-5.
Juliana NCA, Omar AM, Pleijster J, et al. The natural course of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium in pregnant and post-delivery women in Pemba Island, Tanzania. Microorganisms 2021; 9:1180.
Morré SA, van den Brule AJC, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002; 13(Suppl 2):12–18.
Molano M, Meijer CJLM, Weiderpass E, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: A 5-year follow-up study. J Infect Dis 2005; 191:907–916.
Brown SE, Tuddenham S, Shardell MD, et al. Bacterial vaginosis and spontaneous clearance of Chlamydia trachomatis in the longitudinal study of vaginal flora. J Infect Dis 2023; 228:783–791.
Joyner JL, Douglas JM Jr., Foster M, et al. Persistence of Chlamydia trachomatis infection detected by polymerase chain reaction in untreated patients. Sex Transm Dis 2002; 29:196–200.
Renault CA, Israelski DM, Levy V, et al. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health 2011; 8:69–73.
Jordan SJ, Olson KM, Barnes S, et al. Lower levels of cervicovaginal tryptophan are associated with natural clearance of chlamydia in women. J Infect Dis 2017; 215:1888–1892.
van Liere GAFS, Hoebe CJPA, Dirks JA, et al. Spontaneous clearance of urogenital, anorectal and oropharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women, MSM and heterosexual men visiting the STI clinic: A prospective cohort study. Sex Transm Infect 2019; 95:505–510.
Dukers-Muijrers NHTM, Janssen KJH, Hoebe CJPA, et al. Spontaneous clearance of Chlamydia trachomatis accounting for bacterial viability in vaginally or rectally infected women (FemCure). Sex Transm Infect 2020; 96:541–548.
Mott PD, Taylor CM, Lillis RA, et al. Differences in the genital microbiota in women who naturally clear Chlamydia trachomatis infection compared to women who do not clear: A pilot study. Front Cell Infect Microbiol 2021; 11:615770.
Brunham RC, Rekart ML. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis 2008; 35:53–54.
Bakshi RK, Gupta K, Jordan SJ, et al. Immunoglobulin-based investigation of spontaneous resolution of Chlamydia trachomatis infection. J Infect Dis 2017; 215:1653–1656.
McKinnon LR, Achilles SL, Bradshaw CS, et al. The evolving facets of bacterial vaginosis: Implications for HIV transmission. AIDS Res Hum Retroviruses 2019; 35:219–228.
Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004: Associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007; 34:864–869.
Wiesenfeld HC, Hillier SL, Krohn MA, et al. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003; 36:663–668.